Boston Scientific (BSX) Gets Approval for Two Stent Systems Used in Patients with AMI

Boston Scientific Corporation's (NYSE: BSX) ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS Liberte Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. They are the only drug-eluting stent (DES) systems in the U.S. with an approved indication to treat patients with AMI.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Mylan (MYL) Unit Launches Generic Viramune Tabs
• Boston Scientific (BSX) Reports Encouraging Data from PROMUS Element Study;

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter